Glaucocalyxin a prevents hypoxia-induced epithelial-mesenchymal transition in human gastric cancer cells through the PI3K/Akt signaling pathway

References

• Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–713.
   PubMed Web of Science ®Google Scholar
• Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017;39(7):1010428317714626.
   Google Scholar
• Manoochehri Khoshinani H, Afshar S, Najafi R. Hypoxia: a double-edged sword in cancer therapy. Cancer Invest. 2016;34(10):536–545.
   PubMed Web of Science ®Google Scholar
• Parks SK, Cormerais Y, Pouyssegur J. Hypoxia and cellular metabolism in tumour pathophysiology. J Physiol. 2017;595(8):2439–2450.
   PubMed Web of Science ®Google Scholar
• Almendros I, Gozal D. Intermittent hypoxia and cancer: undesirable bed partners? Respir Physiol Neurobiol. 2018;256:79–86.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Wu X, Liu X, et al. Glaucocalyxin A: a review. Nat Prod Res. 2014;28(24):2221–2236.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu S, Zhao L, et al. Effects of glaucocalyxin A on human liver cancer cells as revealed by GC/MS- and LC/MS-based metabolic profiling. Anal Bioanal Chem. 2018;410(14):3325–3335.
   PubMed Web of Science ®Google Scholar
• Tang L, Jin X, Hu X, et al. Glaucocalyxin A inhibits the growth of liver cancer Focus and SMMC-7721 cells. Oncol Lett. 2016;11(2):1173–1178.
   PubMed Web of Science ®Google Scholar
• Mao M, Zhang T, Wang Z, et al. Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo. Biochim Biophys Acta Mol Basis Dis. 2019;1865(6):1214–1225.
   PubMed Web of Science ®Google Scholar
• Zhu J, Sun Y, Lu Y, et al. Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nuclear translocation via regulating PI3K/Akt pathway. Cell Death Dis. 2018;9(6):708
   PubMedGoogle Scholar
• Xiao X, Cao W, Jiang X, et al. Glaucocalyxin A, a negative Akt regulator, specifically induces apoptosis in human brain glioblastoma U87MG cells. Acta Biochim Biophys Sin (Shanghai). 2013;45(11):946–952.
   PubMed Web of Science ®Google Scholar
• Lin W, Xie J, Xu N, et al. Glaucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells. Int J Biol Sci. 2018;14(4):418–426.
   PubMed Web of Science ®Google Scholar
• Yang WH, Zhang Z, Sima YH, et al. Glaucocalyxin A and B-induced cell death is related to GSH perturbation in human leukemia HL-60 cells. Anticancer Agents Med Chem. 2013;13(8):1280–1290.
   PubMed Web of Science ®Google Scholar
• Gao LW, Zhang J, Yang WH, et al. Glaucocalyxin A induces apoptosis in human leukemia HL-60 cells through mitochondria-mediated death pathway. Toxicol in Vitro. 2011;25(1):51–63.
   PubMed Web of Science ®Google Scholar
• Liu X, Xu D, Wang Y, et al. Glaucocalyxin A ameliorates myocardial ischemia-reperfusion injury in mice by suppression of microvascular thrombosis. Med Sci Monit. 2016;22:3595–3604.
   PubMed Web of Science ®Google Scholar
• Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med (Berl). 2007;85(12):1301–1307.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225–239.
   PubMed Web of Science ®Google Scholar
• Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437–447.
   PubMed Web of Science ®Google Scholar
• Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441(7092):437–443.
   PubMed Web of Science ®Google Scholar
• Bakir B, Chiarella AM, Pitarresi JR, et al. EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol. 2020;30(10):764–776.
   PubMed Web of Science ®Google Scholar
• Erin N, Grahovac J, Brozovic A, et al. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715–100794.
   PubMed Web of Science ®Google Scholar
• Loh CY, Chai JY, Tang TF, et al. The E-Cadherin and N-Cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8:1118–1150.
   PubMed Web of Science ®Google Scholar
• D'Angelo E, Lindoso RS, Sensi F, et al. Intrinsic and extrinsic modulators of the epithelial to mesenchymal transition: driving the fate of tumor microenvironment. Front Oncol. 2020;10:1122–1139.
   PubMed Web of Science ®Google Scholar
• Huang L, Wu RL, Xu AM, Epithelial-mesenchymal transition in gastric cancer. Am J Transl Res. 2014;7:2141–2158.
   Web of Science ®Google Scholar
• Li H, Jia Y, Wang Y. Targeting HIF-1α signaling pathway for gastric cancer treatment. Pharmazie. 2019;74(1):3–7.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhang Z, Song C, et al. Glaucocalyxin A reverses EMT and TGF-β1-induced EMT by inhibiting TGF-β1/Smad2/3 signaling pathway in osteosarcoma. Chem Biol Interact. 2019;307:158–166.
   PubMed Web of Science ®Google Scholar
• Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153–189.
   PubMed Web of Science ®Google Scholar
• Spangle JM, Roberts TM, Zhao JJ. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta Rev Cancer. 2017;1868(1):123–131.
   PubMed Web of Science ®Google Scholar
• Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67:11–28.
   PubMed Web of Science ®Google Scholar
• Agani F, Jiang BH. Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets. 2013;13(3):245–251.
   PubMed Web of Science ®Google Scholar
• Huang W, Ding X, Ye H, et al. Hypoxia enhances the migration and invasion of human glioblastoma U87 cells through PI3K/Akt/mTOR/HIF-1α pathway. NeuroReport. 2018;29(18):1578–1585.
   PubMed Web of Science ®Google Scholar
• Zhang J, Guo H, Zhu JS, et al. Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1alpha expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells. Oncol Lett. 2014;7(5):1401–1408.
   PubMed Web of Science ®Google Scholar
• Zhu W, Li Y, Zhao D, et al. Dihydroartemisinin suppresses glycolysis of LNCaP cells by inhibiting PI3K/AKT pathway and downregulating HIF-1α expression. Life Sci. 2019;233:116730.
   PubMed Web of Science ®Google Scholar
• Lee JH, Chinnathambi A, Alharbi SA, et al. Farnesol abrogates epithelial to mesenchymal transition process through regulating Akt/mTOR pathway. Pharmacol Res. 2019;150:104504.
   PubMed Web of Science ®Google Scholar
• Chen M, Lu J, Wei W, et al. Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo. Onco Targets Ther. 2018;11:6705–6722.
   PubMed Web of Science ®Google Scholar